TICKERNOMICS Sign up
Last Update: 2023-10-04 11:35:57
Entasis Therapeutics Holdings Inc ( ETTX ) https://www.entasistx.com
2.19USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
ETTX
0.00%
SPY
36.71%
ETTX
2.10%
SPY
70.96%
-72.66%
ETTX
SPY
262.36%
ETTX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
104.80
75.09
0.07
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.21
8061.18
6.30
-60.86
0.00
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-530933.33
100.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.2928
-188.08
-249.08
-0.12
Other Earnings and Cash Flow Stats:
Entasis Therapeutics Holdings Inc ( ETTX ) Net Income TTM ($MM) is -50.38
Entasis Therapeutics Holdings Inc ( ETTX ) Operating Income TTM ($MM) is -55.50
Entasis Therapeutics Holdings Inc ( ETTX ) Owners' Earnings Annual ($MM) is -45.29
Entasis Therapeutics Holdings Inc ( ETTX ) Current Price to Owners' Earnings ratio is -2.00
Entasis Therapeutics Holdings Inc ( ETTX ) EBITDA TTM ($MM) is -55.40
Entasis Therapeutics Holdings Inc ( ETTX ) EBITDA Margin is 0.00%
Capital Allocation:
Entasis Therapeutics Holdings Inc ( ETTX ) has paid 0.00 dividends per share and bought back 0.0 million shares in the past 12 months
Entasis Therapeutics Holdings Inc ( ETTX ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Entasis Therapeutics Holdings Inc ( ETTX ) Interest-bearing Debt ($MM) as of last quarter is 3
Entasis Therapeutics Holdings Inc ( ETTX ) Annual Working Capital Investments ($MM) are 2
Entasis Therapeutics Holdings Inc ( ETTX ) Book Value ($MM) as of last quarter is 16
Entasis Therapeutics Holdings Inc ( ETTX ) Debt/Capital as of last quarter is 23%
Other Balance Sheet Stats:
Entasis Therapeutics Holdings Inc ( ETTX ) has 33 million in cash on hand as of last quarter
Entasis Therapeutics Holdings Inc ( ETTX ) has 24 million of liabilities due within 12 months, and long term debt 16 as of last quarter
Entasis Therapeutics Holdings Inc ( ETTX ) has 47 common shares outstanding as of last quarter
Entasis Therapeutics Holdings Inc ( ETTX ) has 104 million USD of preferred stock value
Academic Scores:
Entasis Therapeutics Holdings Inc ( ETTX ) Altman Z-Score is 0.00 as of last quarter
Entasis Therapeutics Holdings Inc ( ETTX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Entasis Therapeutics Holdings Inc ( ETTX ) largest shareholder is Virtu Financial LLC owning 20027 shares at 0.04 ($MM) value
Innoviva, Inc.(an insider) Bought 7598814 shares of Entasis Therapeutics Holdings Inc ( ETTX ) for the amount of $16717390.80 on 2022-07-11
66.34% of Entasis Therapeutics Holdings Inc ( ETTX ) is held by insiders, and 10.42% is held by institutions
Entasis Therapeutics Holdings Inc ( ETTX ) went public on 2018-09-26
Other Entasis Therapeutics Holdings Inc ( ETTX ) financial metrics:
FCF:-44.51
Unlevered Free Cash Flow:-62.55
EPS:-1.29
Operating Margin:-530933.33
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-366.72
Beta:-0.12
Buffet's Owners Earnings:-45.29
Price to Owner's Earnings:-2.00
About Entasis Therapeutics Holdings Inc ( ETTX ) :
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.